Adagene INC. (ADAG) — 6-K Filings

6-K Filings (16)

• Adagene Inc. Files 6-K Report — Apr 2, 2026 Risk: low
  Adagene Inc. filed a Form 6-K on April 2, 2026, reporting information as a foreign issuer. The filing includes various exhibits such as the 6-K form itself, and
• 6-K Filing — Apr 2, 2026
• Adagene Inc. Files 6-K Report — Apr 1, 2026 Risk: low
  Adagene Inc. filed a Form 6-K on April 1, 2026, reporting information as a foreign issuer. The filing includes the main 6-K document and an exhibit (EX-99.1). T
• 6-K Filing — Nov 13, 2025
• Adagene Inc. Files 6-K with Q2 2025 Financial Updates — Aug 12, 2025 Risk: low
  Adagene Inc. filed a 6-K report on August 12, 2025, detailing its financial position as of June 30, 2025. The filing includes balance sheet information for the
• Adagene Inc. Files 6-K for Regulatory Update — Jul 15, 2025 Risk: medium
  Adagene Inc. filed a Form 6-K on July 15, 2025, to report a regulatory update on its clinical development. The filing includes a press release detailing this up
• Sanofi Invests Up To $25M in Adagene — Jul 1, 2025 Risk: medium
  On July 1, 2025, Adagene Inc. announced a strategic investment and option exercise by Sanofi. Sanofi Foreign Participations B.V. has agreed to invest up to US$2
• Adagene Reports Updated Phase 1b/2 Study Data — May 22, 2025 Risk: medium
  Adagene Inc. filed a Form 6-K on May 22, 2025, to report updated data from its Phase 1b/2 study of Muzast. The press release, Exhibit 99.1, details these findin
• Adagene Inc. Files 6-K for FY 2024 Results — Mar 24, 2025 Risk: low
  Adagene Inc. filed a Form 6-K on March 24, 2025, reporting its full-year 2024 financial results and providing a business update. The filing includes a press rel
• Adagene Inc. Reports Phase 1b/2 Study Data Update — Jan 27, 2025 Risk: medium
  Adagene Inc. filed a Form 6-K on January 27, 2025, reporting updated data from its Phase 1b/2 study. The filing includes a press release titled "Adagene Announc
• Adagene Inc. Files 6-K, Presents New Research Insights — Nov 7, 2024 Risk: low
  Adagene Inc. filed a Form 6-K on November 7, 2024, reporting on its activities for the month of November 2024. The filing includes a press release titled "Adage
• Adagene Presents at ESMO Congress in September 2024 — Sep 16, 2024 Risk: low
  Adagene Inc. filed a Form 6-K on September 16, 2024, to report its activities for the month of September 2024. The filing includes a press release titled "Adage
• Adagene Inc. Files 6-K with Mid-Year Financial Updates — Jul 25, 2024 Risk: low
  Adagene Inc. filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the first six months of 2024 and the comparable peri
• Adagene Inc. Enters $100M Sales Agreement with Leerink Partners — Mar 29, 2024 Risk: medium
  On March 29, 2024, Adagene Inc. entered into a sales agreement with Leerink Partners LLC. This agreement allows Adagene to potentially sell up to $100 million o
• Adagene Expands ADG126/KEYTRUDA Colorectal Cancer Trial; Data Due 2024 — Feb 9, 2024 Risk: medium
  Adagene Inc. announced on February 9, 2024, the expansion of its clinical collaboration for ADG126 (muzastotug), a masked anti-CTLA-4 SAFEbody, in combination w
• Adagene's ADG126 Shows Clinical Benefit in Colorectal Cancer Trial — Jan 16, 2024
  Adagene Inc. filed a 6-K on January 16, 2024, announcing interim results for its masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in combination with Pembrolizu

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX